I don't think Gerald is getting the deal he wants
Post# of 30028
Posted On: 09/04/2014 11:55:38 AM
I don't think Gerald is getting the deal he wants from BP on LymPro right now and so he is going it alone for the time being. Could there be a partner in 2 months? Sure. But I doubt it. I think LymPro will need to complete it's validation testing in ICONS lab and then start commercializing with Research Firms doing clinical AD trials. After we've more established Lympro's crediblity....some BP will come in and give Gerald what he wants.
If that doesn't happen for a year that is OK with me. I was pleased with the Qualitative Revenue Guidance we got in the CC. If we only RS at .15 cents and up list in November, and start commercializing Lympro in December, I think we'll be fine.
Because I plan on buying more shares on margin, I'd rather buy them in November at .15 cents than buy them in November at .60 cents. That sounds crazy, because of course I'd like the pps to be at .60 cents in November, but I would be hesitant to buy more shares on margin at that price. So it's a trade off: we might have a lower pps in November, but that will afford me the opportunity to buy more shares on margin because we are so undervalued.
Bottom line: I'm absoulutely confident the Lympro revenue machine in January will take care of our pps from that point forward.
We play the hand we're dealt. As I see it, our short term strength is LymPro revenue and our longer term strength is MANF, Eltoprazine, & Phenoguard. As long as management makes sure we meet the requirements to up list in 2014, I am OK with whatever the pps does now.
If that doesn't happen for a year that is OK with me. I was pleased with the Qualitative Revenue Guidance we got in the CC. If we only RS at .15 cents and up list in November, and start commercializing Lympro in December, I think we'll be fine.
Because I plan on buying more shares on margin, I'd rather buy them in November at .15 cents than buy them in November at .60 cents. That sounds crazy, because of course I'd like the pps to be at .60 cents in November, but I would be hesitant to buy more shares on margin at that price. So it's a trade off: we might have a lower pps in November, but that will afford me the opportunity to buy more shares on margin because we are so undervalued.
Bottom line: I'm absoulutely confident the Lympro revenue machine in January will take care of our pps from that point forward.
We play the hand we're dealt. As I see it, our short term strength is LymPro revenue and our longer term strength is MANF, Eltoprazine, & Phenoguard. As long as management makes sure we meet the requirements to up list in 2014, I am OK with whatever the pps does now.
(0)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼